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Abstract
Objective: To investigate the antigenic effect of a peptide containing two epitopes of Chlamydia pneumoniae (Cpn) on
atherosclerotic lesion formation in mice infected with Cpn.
Materials and Methods: Six-week-old Apobtm2SgyLdlrtm1Her/J mice were immunized using a repetitive immunization
multiple-sites strategy with KLH-conjugated peptides derived from the major outer membrane protein and the putative
outer membrane protein 5 of Cpn. Mice were fed a high-fat diet and infected with Cpn twice during the 10-week diet period.
Lesions were evaluated histologically; local and systemic immune responses were analyzed by immunohistochemistry of
aorta samples and cytokine measurements in plasma samples and splenocyte supernatants.
Results: Mice immunized with the combined Cpn peptide showed a greater reduction in lesion size compared to mice
immunized with either epitope alone [54.7% vs 39.8% or 41.72%] and was also associated with a significant decrease in
lesion area in descending aortas compared with those in controls (88.9% for combined Cpn peptide, 81.9% for MOMP
peptide and 75.7% for Omp5, respectively). This effect was associated with a shift in the cellular composition of plaques
towards decreased inflammatory cell and increased regulatory T-cell content. Additionally, the effect was also connected
with decreased secretion of proinflammatory cytokines and increased production of anti-inflammatory cytokines
demonstrated in plasma and in supernatant on stimulated spleen cells.
Conclusions: Atherosclerotic lesion formation may be promoted by Cpn infection in the presence of a high-fat diet, and
reduced by immunization with the combined Cpn peptide. The combined peptide has more potential than either epitope
alone in reducing atherosclerotic lesion development through Treg expansion.
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Introduction
Chlamydia pneumoniae (Cpn) [1] is an important human pathogen
that causes atypical pneumonia and is associated with various
chronic inflammatory diseases such as atherosclerosis, a major
cause of cardiovascular disease and death in the Western world
[2–6]. Although the epidemiological importance of Chlamydia
infection in atherosclerosis is not well defined, the potential role of
Cpn in coronary atherosclerosis may be related more to
acceleration of the disease or to the systemic effects of persistent
infection than to sudden initiation of infarction by acute infection
[7]. However, the theoretical role of Cpn in acceleration of
atherosclerosis is still controversial [8–10]. Although an association
between Cpn infection and coronary atherosclerosis has been
reported, the association is less clear for the effect of peptide
antigen derived from Cpn on the formation of atherosclerotic
lesion. In addition, an epitope of the major outer membrane
protein (MOMP) of Cpn (AA 67–74: GDYVFDRI) and the
putative outer membrane protein 5 (Omp5) of Cpn (AA 284–292:
QAVANGGAI) share high homology, with two sequence loca-
tions of ApoB protein (http://web.expasy.org/sim/). ApoB
protein plays a crucial role in atherosclerosis as immunization
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with some peptides derived from ApoB protein reduce atheroscle-
rotic lesion in several mouse models. Indeed, this molecular
mimicry (share high homology) was recently demonstrated in our
laboratory in which an epitope containing both sequences of AA
67–74 (GDYVFDRI) and AA 284–292 (QAVANGGAI) has an
effect on atherosclerotic lesion reduction in a protein scaffold in
non-infected mice with Chlamydophia [11]. In this study, we
investigate the effect of a linear peptide containing these two
putative epitopes derived from MOMP and Omp5 of Cpn on
atherosclerotic lesion formation in Cpn-infected Apobtm2Sgy
Ldlrtm1Her/J mice.
Materials and Methods
The immunizing peptides derived from MOMP (AA 67–74:
GDYVFDRI, designated as MOMP peptide) and Omp5 (AA
283–291: QAVANGGAI, designated as Omp5 peptide), and a
combined peptide containing the MOMP and the Omp5 peptides
(designated as a combined Cpn peptide) coupled by a polyglycine
[(Gly)5] linker, were used in this study in a Keyhole limpet
hemocyanin (KLH)-conjugated form. All of the peptides used in
the study, including ApoB peptide and human HSP60 (hHSP60)
peptide, were synthesized by Severn biotech Ltd (Worcestershire,
UK).
Animal Experiments
The experiments were approved by the Animal Welfare
Committee of the University of Szeged and conform to the
Directive 2010/63/EU of the European Parliament.
Apobtm2SgyLdlrtm1Her/J mice (these mice produce ApoB100
only, and are LDL receptor deficiency).were used in our study in a
total of 5 groups (3 sample and 2 control groups). Each group
included 6 mice (5–6-week-old males; similar body weight,
32.2662.12 g [measured at the end of the experiment]) and the
experiment was repeated. Mice were immunized with KLH-
conjugated peptides mixed with Alum adjuvant subcutaneously
according to a repetitive immunization multiple sites strategy
(RIMMS) as described earlier [11,12]. For infection, mice were
inoculated intranasally with 26106 inclusion forming units (IFU)
of Cpn (CV-6, cardiovascular strain) [13] in 25 mL of phosphate
buffered saline (PBS) at week 4 and at week 8. This dose was
chosen based on survival and symptoms observed in mice after
infection with different infection doses (Table S1). CV-6 strain of
Cpn was propagated in HEp-2 cells and partially purified as
described earlier [14]. The mice were sacrificed at the end of week
12 (a high-fat diet was started at week 2 and continued for 10
weeks). For detection of Cpn-specific DNA, polymerase chain
reaction (PCR) was performed as described by Tong and Sillis
[15]. The MOMP of Cpn was chosen as a target for amplification
in a nested PCR. All primers were synthesized in Life Technol-
ogies Ltd (Paisley, UK). The external primers (Table S2) amplified
a 333 base-pair product (first-stage PCR) from the genomic DNA
purified from lung homogenates of tested mice in both infected
and non-infected (negative control) groups. The internal primers
amplified a 207 base-pair product (second-stage PCR) using the
first-stage PCR product as a template. To confirm if the mice were
infected, further detection of Cpn-specific IgG in the mouse sera by
indirect immunofluorescence was carried out. A HEp-2 cell
(ATCC) monolayer grown on 13-mm coverslips in 24-well plates
was infected with Cpn (CWL029) at a multiplicity of infection
(m.o.i.) of 1. At 48 h of infection, cells were fixed with ice-cold
acetone (10 min, 220uC). PBS-rehydrated cells were stained with
Cpn MOMP-specific mouse monoclonal antibody (DAKO,
Budapest, Hungary) and FITC-labelled anti-mouse IgG secondary
antibody (SIGMA, Dorset, UK). Coverslips were examined under
an ultraviolet-microscope, and evenly distributed bright fluoresc-
ing inclusions were visible. Mouse sera diluted in PBS were used as
the primary antibody for staining the similarly treated monolayers
and the same FITC-conjugated secondary antibody was applied to
detect serum IgG binding to inclusions. Reciprocal of serum
dilution producing clearly discernable inclusions was determined
as Cpn-specific titre of the mouse serum. The repetitive immuni-
zation multiple-sites strategy (RIMMS) was adopted [9,10] and
mice were sacrificed at the end of week 12 (a high-fat diet was
started at week 2 and continued for 10 weeks).
Serum Lipoprotein Analysis
Serum total cholesterol, triacylglycerol and high-density lipo-
protein (HDL) were measured with a Modular P800 assay system
(Roche, Mannheim, Germany) through a service from the
Department of Laboratory Medicine, University of Szeged,
Hungary. Low-density lipoprotein (LDL) cholesterol was calculat-
ed according to the Friedewald formula:
LDL concentration mmol=Lð Þ~
X
cholesterol{ HDLz triacylglycerol|0:46ð Þ½ 
Tissue Preparation and Antibody Response
Measurements
Twelve weeks after the first immunization, tissues were
harvested and mounted in Optimal Cutting Temperature (OCT)
for immunohistochemical analyses and in paraffin for lesion
measurement. Atherosclerosis in aortic roots was examined by
Image-Pro Plus TM software, version 4.0 ((Media Cybernetics,
Bethesda, MD, USA). Peptide-specific antibody titers were
measured by ELISA following the manufacturer’s instructions.
To assess whether immunization with the combined Cpn peptide
led to changes in lipoprotein profiles, the cholesterol, triglyceride,
HDL- and LDL-cholesterol profiles of the mice were analyzed
using a pooled plasma sample from each group after being fed a
high-fat diet for 10 weeks.
Immunohistochemical Analyses, Morphometric Analyses
and Quantitative Measurements of Atherosclerosis
OCT-embedded samples were used for immunohistochemical
analyses. Sections of paraffin-embedded tissues were stained with
hematoxylin and eosin (HE) and elastin/van Gieson (Sigma) for
histological examination and were evaluated using an Olympus U-
ULH Optical microscope (Olympus Optical Co. Ltd, Tokyo,
Japan).
Both the atherosclerotic lesions in the aortic sinus and the
lesions in the descending aortas were measured. The descending
aortas were evaluated for the extent of atherosclerosis.
Measurement of Cytokines
Plasma levels of interleukin (IL)-10, transforming growth factor
(TGF)-b, tumor necrosis factor (TNF)-a and interferon (IFN)-c
were measured by ELISA following the manufacturer’s instruc-
tions (R&D systems, Abingdon, UK). IL-10 and TNF-a levels in
the lesions were quantified by immunohistochemical analyses (rat
anti-mouse TNF-a and IL-10 purchased from BioLegend, CA,
USA). Levels of concanavalin-A (Con A)-induced IL-10, TGF-b,
TNF-a and IFN-c in splenocyte cultures were also measured.
Peptide Immunization and Atherosclerotic Lesions
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Fluorescence Activated Cell Sorting Analysis
Spleen cells from mice immunized with either Cpn peptides or
KLH (control) were used for T regular (Treg) cells measurement
using a Treg detection kit (Miltenyi Biotec, Surrey, UK). Cells
were analyzed with a Beckman-Coulter FC-500 Analyzer (Bach-
man Coulter, High Wycombe, UK).
Statistical Analyses
Data are reported as mean6standard error of the mean
(6SEM), unless otherwise indicated. Figures were plotted using
graph-pad Prism 5.01 and Sigma plot 9.0. For atherosclerotic
lesion size, data were compared and intergroup differences were
conducted using one-way ANOVA for multiple comparisons and
post hoc bonferroni test. Other data were analyzed using Student’s
t-test (2-tailed analyses). Non-parametric distributions were
analysized using Mann-Whitney U test for pairwise comparisons
and the Kruskal-Wallis test for multiple comparisons. Differences
between groups were considered significant at P values below 0.05.
Results
Detection of Cpn Infection
The MOMP of Cpn was chosen as a target for amplification in
nested PCR DNA from infected samples only, and produced a
band of the expected size after the first PCR amplification.
Similarly, in the second amplification, a positive band of the
correct size was obtained only from using the first PCR product as
a template originally from infected and non-infected mice
(Figure 1). Cpn DNA was detected from the lung homogenates
by PCR as shown in Figure 1a, and the primers used for PCR as
shown in Table S1. In addition, a genus specific epitope within
Chlamydia lipopolysaccharde (LPS) was detected from the lesion
sites of aortic sinus in Cpn-infected mice by Chlamydia LPS antibody
(MCA 2718, AbD serotec) compared that of mice without Cpn
infection (control), suggesting that Cpn bacteria were captured at
the lesion site when mice were infected with Cpn bacteria as shown
in Figure 1b.
Peptide-Specific Immunoglobulin G in Sera of
Immunized Mice
A peptide-induced specific antibody response was observed
when the MOMP peptide, the Omp5 peptide and the combined
Cpn peptide were used as ELISA antigens (Figures 2A–D), when
compared with a KLH control, which produced little immune
response (Figures 2C and D). The antibody immune response at
week 12 was slightly lower than that at week 2 (Figure 2A–D) apart
from combined Cpn peptide-induced antibody at week 12. High
antibody concentrations against either the Omp5 peptide or the
MOMP peptide at week 2 were detected in immunized mice
despite a relatively lower immune response in the MOMP-
peptide-immunized mice than in the Omp5-peptide-immunized
mice at week 12.
Peptide-Specific Immunoglobulin Subtypes G1 and G2a
in Antiserum of Immunized Mice
A peptide-induced specific IgG1 response was observed, when
compared with a KLH control (Figure 2E). There was little or no
IgG2a immune response (Figure 2F) in pooled antiserum.
Immunization with a KLH-conjugated ApoB and hHSP60
peptides was described earlier [11]. Sera from these experiments
and sera of Cpn peptide-immunized mice were used for testing
cross-reaction of peptide-specific antibodies. ApoB and Cpn
peptides, individually, induced high levels of peptide-specific IgG
in mouse sera two weeks after the first immunization compared to
the control group immunized with KLH alone. Certain level of
cross-reaction was observed between ApoB peptide and Cpn
peptide antisera (Figure 2G), as well as between Cpn peptide and
ApoB peptide antisera (Figure 2H) [16].
Effect of Treatment With Cpn Peptides on Plasma Lipid
Levels
Slightly lower concentrations of cholesterol and LDL were
observed in the infected control mice than in the non-infected
controls (Table 1). In agreement with previous report by Blessing
et al, there was no significant difference observed between the
infected and non-infected mice [17]. In addition, there was little
change in either triglyceride or HDL concentration observed in
non-infected and infected control mice as well as in mice infected
after immunization with the combined Cpn peptide. These levels
were remained the same as those in infected mice after
immunization with the combined Cpn peptide.
Reduction of Atherosclerotic Lesion Size in the Aortic
Sinus
Representative sections from the aortic sinuses of mice are
shown in Figure 3A. The lesion size in infected control mice was
5% larger than that in non-infected controls (32% vs. 27%), but it
did not show significant. In contrast, the lesion size in mice
immunized with the combined Cpn peptide was smaller than that
in either the MOMP peptide- or the Omp5-peptide–immunized
mice (14% vs. 19% and 14% vs. 18%, respectively) (Figure 3B).
The former pair of peptide antigens showed significant difference
(P=0.045), but this was not in case of the later pairs (P=0.05). No
significant difference in lesion size between mice immunized with
either the MOMP peptide or the Omp5 peptide alone was
observed.
Reduction in lesion size, expressed as a percentage of the lesion
size in the aortic sinus of the control mice, was 54.7% following
immunization with the combined Cpn peptide versus 39.8% with
the MOMP peptide and 41.7% with the Omp5 peptide
(Figure 3C). In addition, the lesion reduction in mice immunized
with the combined Cpn peptide was significantly greater (P=0.046)
than that in MOMP peptide- immunized mice (Figure 3C).
In addition, we assessed oil red O (ORO) lipid levels in
atherosclerotic lesions in the aortic sinus. Representative sections
from the aortic sinuses of mice are shown in Figure S1A. The lipid
level at the lesion sites in infected control mice was approximately
7-fold higher than in the MOMP-peptide-immunized mice (32.5%
versus 4.6%, respectively), 6- fold higher than in the Omp5-
peptide-immunized mice (32,5% versus 5.2%, respectively) and 9-
fold higher than in the combined Cpn peptide-immunized mice
(32.5% versus 3.6%, respectively) (Figure S1B). Lipid level in mice
immunized with the combined peptide was significantly lower
than that in either the MOMP-peptide-immunized mice (4.6%
versus 3.6%, P=0.028) or the Omp5-peptide-immunized mice
(5.2% versus 3.6%, P=0.001), respectively.
Furthermore, we examined the impact of treatment with Cpn
peptides on the collagen in these lesions. The reduction of
atherosclerosis in mice treated with these peptides was associated
with an increased collagen content: 4-fold for the combined Cpn-
peptide-immunized mice versus control mice (24.461.2% versus
5.960.5%; P,0.001), 3-fold for the MOMP peptide-immunized
mice (19.461.3% versus 5.960.5%; P,0.001), and 3-fold for the
Omp5 peptide-immunized mice (18.961.5% versus 5.960.5%;
P,0.00) (Figures S2A and B), respectively. Mice immunized with
the combined peptides showed a significant collagen increase
Peptide Immunization and Atherosclerotic Lesions
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compared to mice immunized with either the MOMP- or the
Omp5-peptide alone (P= 0.007 and P= 0.004, respectively).
Reduction of Atherosclerotic Lesion Size in Descending
Aortas
Lesion size in the descending aortas of infected control mice was
greater than that in non-infected control mice (32.0% vs. 17.0%,
P,0.01) (Figure 4A). Lesion size in the descending aortas in mice
immunized with the combined peptide was smaller than that in
either the MOMP-peptide-immunized (3.4% vs. 5.8%) or the
Omp5-peptide-immunized (3.4% vs. 7.8%) mice respectively
(Figure 4B). There was, however, no significant difference in
lesion size between mice immunized with either the MOMP
peptide or the Omp5 peptide, or between mice immunized with
either the MOMP peptide or the combined Cpn peptide; a
significant difference (P,0.01) was found between mice immu-
nized with the Omp5 peptide versus the combined Cpn peptide.
Reduction in lesion size, expressed as a percentage of lesion size in
descending aortas, was 88.9%, 81.9% and 75.7% from mice
immunized with the combined Cpn peptide, the MOMP peptide
and the Omp5 peptide, respectively, showing a similar trend to
that observed in aorta sinus (Figure 4C). The calculated
percentage reduction in lesion size showed a significant difference
(P=0.006) between mice immunized with the Omp5 peptide
versus the combined Cpn peptide (Figure 4C).
Amount of Inflammatory Cells in The Atherosclerotic
Lesions
The percentage of macrophage-occupied area in the lesions in
mice immunized with the combined peptide was 7.8%, signifi-
cantly lower than that in mice immunized with the Omp5 peptide
(12.2%, P=0.016), but not with the MOMP peptide (12.3%,
P=0.084) alone. In contrast, mice immunized with the KLH
showed a 34.1% occupation (Figures 5A and B).
The proportion of anti-CD11c+-stained lesion area was
5.260.4% in mice immunized with the combined Cpn peptide,
lower than that with either the MOMP peptide (8.360.5%,
P= 0.006) or the Omp5 peptide (8.460.5%, P=0.002) alone, and
the control group (32.962.8%, P,0.001) (Figure 5C). In addition,
the proportion of anti-CD11c+-stained lesion area co-localized
with CD68+ was 71.264.5% for the combined peptide,
77.769.5% for the MOMP peptide and 74.667.0% for the
Figure 1. 1a. Agarose gel electrophoresis of PCR products (first stage, lanes 2–6; second stage, lanes 8–12). Lanes 2 and 3 using genomic DNA as a
template from two Apobtm2SgyLdlrtm1Her/J mice infected with Cpn bacteria; lanes 5 and 6 using genomic DNA from two non-infected
Apobtm2SgyLdlrtm1Her/J mice; lanes 8, 9, 11 and 12 using first-stage PCR products 2, 3, 5 and 6 as a template, respectively. Lanes 1 and 7 show the
Phi174 DNA/HaeIII maker (Promega). 1b. Chlamedia LPS antibody (MCA 2718, AbD serotec) stained lesion sites in aortic sinus. Chlamedia LPS
antibody (MCA 2718, AbD serotec) was used as the first antibody (10 mg/ml), anti-mouse IgG-FITC, developed in sheep, was used as a second
antibody. Green represents Chlamedia LPS and blue represents cell nnucleuses stained with 49,6-diamidino-2-phenylindole (DAPI) (Vector Lab,
Peterborogh, UK) [N = 6 mice].
doi:10.1371/journal.pone.0081056.g001
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Omp5 peptide, compared with 95.760.8% for the controls
(Figure 5D).
Forkhead box P3 (Foxp3) is a transcriptional regulator of
CD4+CD25+ regulatory T cells [18]. Thus, we chose to investigate
whether the compromised suppressor function of Tregs observed
in mice immunized with these peptides was associated with Foxp3
up-regulation. We found that the CD4+-occupied area in the
lesion was significantly reduced in mice immunized with these
peptides (P,.0.001) compared with that of control mice immu-
nized with the KLH only (33086268 mm2 versus
10,60761435 mm2 for the MOMP peptide, 27796525 mm2
versus 10,60761435 mm2 for the Omp5 and 17616359 mm2
versus 10,60761435 mm2 for the combined Cpn peptide, respec-
tively) (Figures 5E and F). In addition, the CD4+-occupied area in
lesions in mice immunized with the combined Cpn peptide
developed significantly smaller occupied areas in lesions than
those of mice immunized with the MOMP peptide (P= 0.006)
(Figures 5E and F). In contrast, the proportion of Foxp3+ area co-
localized with CD4+ area in mice immunized with these peptides
was increased compared with that in control mice immunized with
the KLH alone, showing 21.4% (P=0.001) for the combined Cpn
peptide, 8.4% (P=0.006) for the MOMP peptide, and 10.0%
(P,0.001) for the Omp5 peptide, versus 1.1% for the control
(Figures 5E and G). In addition, a statistically significant difference
(P,0.05) was observed between the combined Cpn peptide and
either theMOMP peptide or the Omp5 peptide (Figures 5E and G).
Consistently, the flow cytometric analysis of spleen cells showed
significantly increased expression of Foxp3+ in mice immunized with
these peptides compared with that of the KLH control mice (P#0.001,
Figures 5H and I). Similar to the observation in the lesions, higher
expression of Foxp3+was found inmice immunized with the combined
Cpn peptide than those of mice immunized with either the MOMP
peptide (P=0.006) or the Omp5 peptide (P=0.003).
Expression of Anti-Inflammatory Cytokines and Pro-
Inflammatory Cytokines
To further characterize the effect of immunization with the
combined Cpn peptide, we analyzed IL-10 expression in aortic
Figure 2. (A–C) Concentration of Cpn peptide-induced IgG antibodies and KLH controls in the sera of Apobtm2SgyLdlrtm1Her/J mice at 2 and 12 weeks
after the first immunization. The mean optical densities (ODs) were obtained from plasma samples of each peptide-immunized mouse on relevant
peptide-coated ELISA plates. Dilution ratio: 1:100. (D, E) Concentrations of Cpn peptide-induced IgG1 and IgG2a antibodies in the sera of
Apobtm2SgyLdlrtm1Her/J mice at 2 weeks after the first immunization. Dilution ratio: 1:400 for IgG1 and 1:50 for IgG2a. (F, G) Cross-reaction between the
combined Cpn peptide and ApoB peptide (the data of Fig. 2F were from individual samples, the data of Fig. 2G were from pooled samples).
doi:10.1371/journal.pone.0081056.g002
Table 1. Plasma lipid concentrations in mice after being fed a high-fat diet for 10 weeks.
Immunization Diet (weeks)
Cholesterol
(mmol/l) TRI* (mmol/l) HDL* (mmol/l) LDL* (mmol/l)
LKH-combined Cpn peptide-Cpn-infected mice 10 36.09 2.11 5.78 29.35
LKH-Cpn-infected mice 10 28.87 1.77 5.20 22.87
LKH-non-Cpn-infected mice 10 34.65 2.56 5.33 28.16
*Calculated values.
doi:10.1371/journal.pone.0081056.t001
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lesions of mice immunized with these peptides (Figure 6A).
The proportion of CD4+ cells expressing IL-10 was signifi-
cantly higher in mice immunized with the combined Cpn
peptide compared with control mice (.2-fold; 9.0% versus
3.6%, P= 0.024). Mice immunized with either the MOMP
peptide or the Omp5 peptide showed similar proportions of
IL-10 (6.0% and 5.6%, respectively) and showed significantly
higher proportions in lesion sites compared with that in
controls (P,0.05). Mice immunized with the combined Cpn
peptide had a greater IL-10-positive area compared with
either the MOMP peptide or the Omp5 peptide alone; but
this increased level did not show statistical significance
(Figure 6B).
Immunohistochemical analyses of TNF-a showed significantly
smaller TNF-a-occupied areas in lesions of mice immunized with
the combined Cpn peptide compared with controls (6.0% for the
combined peptide vs. 9.2% for the MOMP peptide, 9.0% for the
Omp5 peptide and 22.4% for the controls). The difference was
statistically significant for the MOMP peptide (P,0.05), but not
for the Omp5 peptide when compared with the combined Cpn
peptide (Figures 6C and D).
Level of Atheroprotective and Atherogenic Cytokines in
Plasma and in Supernatants of Stimulated Splenocytes
Plasma levels of atheroprotective cytokine IL-10 (P,0.05) and
TGF-b (P,0.01) were significantly increased in mice immunized
with the combined Cpn peptide compared with either the MOMP
peptide or the Omp5 peptide (Figures 7A and B). The levels of
these two cytokines were also significantly increased in mice
immunized with either the MOMP peptide (P,0.05) or the Omp5
peptide (P,0.05) (Figures 7A and B) versus controls. Plasma levels
of TNF-a were significant reduced by immunization with the
combined peptide compared with either the MOMP (P,0.05) or
the Omp5 peptide (Figure 7C); all peptides produced a reduction
in TNF-a secretion versus controls. A similar trend was obtained
for these peptides in respect of plasma levels of IFN-c (Figure 7D).
Although no statistically significant difference was found between
the combined Cpn peptide and the MOMP peptide, a significant
difference in IFN-c levels was found in mice immunized with the
combined Cpn peptide compared with the Omp5 peptide (P,0.05)
(Figure 7D).
In addition, supernatants of the splenocytes from mice
immunized with these peptides individually showed significantly
Figure 3. Detection and quantitation of the lesion areas in the aorta of Apobtm2SgyLdlrtm1Her/J mice fed a high-fat diet after
immunization with each peptide antigen versus control mice immunized with KLH only (both infected and non-infected). (A)
Representative photomicrographs of lesions observed in atherosclerotic aortas as analyzed with elastin/van Gieson staining. (B) Percentage of luminal
surface occupied by lesions in the aortic sinus versus control mice immunized with KLH (ratio of lesion areas [mm2] versus total areas [mm2] [N= 6
mice]). (C) Reduction of lesion size shown as percentage of the lesion area versus that in control mice (infected). Data represent mean 6 SEM.
doi:10.1371/journal.pone.0081056.g003
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increased secretion of IL-10 (Figure 7E) and TGF-b (Figure 7F),
stimulated with 10 or 100 mg/mL of Con A (P,0.001). The
incremental secretion of IL-10 and TGF-b in the combined Cpn
peptide-immunized mice was significantly higher than either the
MOMP or the Omp5 peptide-immunized mice (P,0.05).
Significantly decreased secretion of TNF-a (Figure 7G) and IFN-
c (Figure 7H) was found in the supernatants of splenocytes in mice
immunized with these peptide antigens. A significantly greater
decrease in the secretion of TNF-a was observed in mice
immunized with the combined Cpn peptide versus immunized
with either the MOMP peptide or the Omp5 peptide alone
(Figure 7G; P,0.05) stimulated with 100 mg/mL of ConA
(P,0.05). A significantly greater decrease in secretion of IFN-c
was detected in the combined Cpn peptide-immunized mice versus
those in either the MOMP-peptide or the Omp5 peptide-
immunized mice (Figure 7H, P,0.05), stimulated with 10 or
100 mg/mL of ConA (P,0.05).
Furthermore, IL-10 concentration was significantly higher in
the supernatant of spleen cells from the combined Cpn peptide-
immunized mice stimulated by the same antigen peptide than
that after stimulation by PBS (P,0.05, Figure 7I). In contrast,
IFN-c was significantly lower in supernatant of spleen cells from
the combined Cpn peptide-immunized mice stimulated by the
same antigen peptide than that of mice stimulated by PBS
(P,0.05, Figure 7J). In the similar experimental conditions,
supernatant of spleen cells from the naive mice failed to show
these differences.
Moreover, CD4+ expressing IL-17A levels in splenocytes from
immunized mice with either Cpn peptides or KLH alone were also
assessed. Representative flow cytometric plots for population of IL-
17A in CD4+ T cells from splenocytes are shown in Figure S3A.
CD4+ expressing IL-17A level in control mice was 3.2% larger
than the MOMP peptide-immunized mice (5.0% versus 1.8%),
2.4% larger than the Omp5-peptide-immunized mice (5.0%
versus 2.6%), and 3.8% larger than the combined Cpn-peptide-
immunized mice (5.0% versus 1.2%) (Figure S3B). In addition, a
significant difference was observed between the combined Cpn-
peptide-immunized mice and either the MOMP-peptide-
(P,0.011) or the Omp5-peptide-immunized mice (P,0.011) as
well as between the MOMP-peptide- and the OMP5-peptide-
immunized mice (P,0.001).
Evaluation of Antigen-Induced Specific Treg Function
and Specific Cellular Immune Response
To assess whether functional Treg cells were induced by
immunization, we co-cultured antigen-specific Treg cells with
CD4+ effector T-cells (CD4+CD25- T-cells). Proliferation of
effector T-cells from control mice immunized with KLH in
response to stimulation with KLH at 1 mM did not show
suppression in a dose-dependent manner in the presence of Treg
cells from KLH-immunized mice (Figures. 8A, B and F). In
contrast, Inhibition of effector T- cell proliferation was achieved
from sampling mice immunized with either the MOMP peptide
(Figures 8A, C and F), or the Omp5 peptide (Figures 8A, D and F)
Figure 4. Detection and quantitation of lesion areas from en face descending aorta of Apobtm2SgyLdlrtm1Her/J mice fed a high-fat
diet after immunization with each peptide antigen versus control mice immunized with KLH only. (A) Representative stained en face
descending aorta from mice infected with Cpn. (B) Percentage of lesion-occupied area versus total area. (C) Percentage reduction of the lesion. Data
represent mean 6 SEM. *P,0.05; ** P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0081056.g004
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as well as the combined peptide (Figures 8A, E and F), when co-
cultured CD4+CD252 effector T cells with CD4+CD25+ Treg cells
isolated from these mice in response to stimulation with related
antigen. The differences were significant when adding Tregs to the
effector cells at the ratios between 4:1,16:1 (P,0.05,,0.001)
compared with that without the addition of Tregs. Additionally, the
differences were significant when compared different concentration
of added Treg in sampling mice at the ration between 4:1,16:1 of
Treg and T effector cells (P,0.05,,0.001).
Discussion
In this study, we investigated the effect of the combined peptide
derived from Cpn proteins of MOMP and Omp5 in modulating
experimental atherosclerosis in Apobtm2SgyLdlrtm1Her/J mouse-a
strain that develops high levels of atherosclerosis after being fed a
high-fat diet [16]. The effect of immunization with the combined
peptide was compared with that of the two peptides used singly.
The two peptides were selected for coupling based on our
hypothesis that they share high homology with ApoB protein
which is associated with atherosclerosis.
In line with previous reports by Blessing et al [17] and Ezzahiri
et al [19], our results showed that infection of mice with
Cpnbacteria promotes the formation of atherosclerotic lesion.
Unlike that reported by Blessing et al, our results did not show
statistical significance on promoting the lesion in mice infected
with Cpn bacteria compared with that of uninfected mice following
feeding with a high-fat diet for 10 weeks. These results suggest that
Figure 5. (A–D) Assessment of inflammation-associated cells in the lesions of Apobtm2SgyLdlrtm1Her/J mice fed a high-fat diet after immunization with
peptide antigens. (A) Representative photomicrographs showing immunohistochemical staining of CD68 (green) and CD11c (red) markers,
respectively. Percent occupied lesion (vs. infected control) for (B) CD68 and (C) CD11c. Magnification: 4006. Data represent the mean value 6 SEM.
(D) Assessment of inflammation-associated cells as percentage of CD11c areas co-localized with CD68 area (N= 6 mice). (E–G) Assessment of CD4+
Treg cells in the lesions of Apobtm2SgyLdlrtm1Her/J mice fed on a high-fat diet after immunization with peptide antigens. (E) Representative
photomicrographs showing immunohistochemical staining of CD4+ (green) and Foxp3+ Treg (red) cells. Magnification 8006. (F) Observation of CD4+
occupied lesion area (N= 6 mice). (G) Assessment of Treg cells as percentage of Foxp3+ areas co-localized with CD4+ area (N= 6 mice). (H)
Representative flow cytometric plots for CD4+CD25+Foxp3+ (Treg) cell population in spleen cells. Spleen cells from mice immunized with either Cpn
peptides or KLH (control) were performed using a Treg detection kit (Ailtenyi Biotec, Surrey, UK) according to manufacturer’s protocols. (I) Bar chart
presentation of flow cytometric analysis. Data represent mean6SEM of data from 3 independent samples.
doi:10.1371/journal.pone.0081056.g005
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feeding with a high-fat diet for longer than 10 weeks may be
necessary to form sufficient lesion area, as the data from Blessing et
al have shown that the fast lesion increasing time seems between
10–16 weeks [17]. Additionally, other factors, such as different
mouse or bacterial strains and different inoculating doses may also
affect lesion formation. We report the novel finding that either the
MOMP peptide or the Omp5 peptide significantly reduces
atherosclerotic lesion when used as a peptide antigen in
Apobtm2SgyLdlrtm1Her/J mice infected with Cpn bacteria. A
different study was shown that a recombinant protein containing
both of the MOMP peptide and the Omp5 peptide sequence
significantly reduced atherosclerotic lesion in non-infected mice
[11], indicating infection of mice with Cpn is an independent factor
for functional study of these two peptides. The mechanism of this
function may be due to molecular mimicry, as the combined Cpn
peptides can cross-react with antiserum induced by human ApoB
peptide (also called ApoB100661–681 peptide). Although certain
level of cross-reaction was observed between ApoB peptide and
Cpn peptide antisera, strong cross-reaction (approx net 1.5 OD
value) between Cpn peptide and ApoB peptide antisera was
striking. In fact, autoantibodies to this ApoB peptide as well as to
other ApoB100 peptides are present in human plasma and are
associated with decreased cardiovascular risk. In addition,
immunization with this peptide reduces atherosclerotic lesion in
several knock-out mouse models including LDL receptor2/2/
human ApoB-100 mice [20], ApoE2/2 mice [21] and Apobtm2Sgy
Ldlrtm1Her/J mice [16]. Vaccination with a modified Streptococcus
pneumoniae (Spn) has been reported to decrease atherosclerotic
lesion formation through molecular mimicry between Spn and
oxidized low-density lipoprotein (oxLDL) [22], which has been
demonstrated to play a role in the development of atheroscle-
rotic lesions [23,24]. Immunization of oxLDL or apolipoprotein
B (ApoB) peptide of oxLDL reduces atherosclerotic lesion
formation [16,25] in either ApoE2/2 or Apobtm2SgyLdlrtm1Her/
J mouse models. However, molecular mimicry can occur in the
absence of any true sequence homology between Cpn-derived
peptide and ApoB peptide by using the computer-based
software ‘SIM-Alignment Tool’ for protein or peptide sequences
(http://web.expasy.org/tools/sim), in agreement with the
report by Kohm et al [26]. In this case, it could explain why
antigenic surfaces, rather than sequence homology, dictate
molecular mimicry [27].
Figure 6. Assessment of interleukin-10-producing T cells and tumor necrosis factor-a expression in the lesions of
Apobtm2SgyLdlrtm1Her/J mice fed a high-fat diet after immunization with peptide antigens. (A) Representative photomicrographs
showing dual-immunohistochemical staining for IL-10 (red) and CD4 (green). (B) Percentage of IL-10-positive area co-localized with CD4+ area. (C)
Relative ratio of immunohistochemical stained area (green) for TNF-a in the lesion versus total lesion area. (D) Percentage reduction of TNF-a-positive
area versus that in the control mice (N= 6 mice).
doi:10.1371/journal.pone.0081056.g006
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The data from our present study also demonstrate that
reduction of the lesion, either in the aortic sinus or the descending
aorta, in mice immunized with the combined Cpn peptide is
significantly greater than with either the MOMP- or the Omp5-
peptide alone. In addition, the reduction in lipid level at lesion
sitesin mice immunized with the combined Cpn peptide is
significantly greater than that in mice immunized with either the
MOMP or the Omp5 peptide alone. Furthermore, the reduction
of atherosclerotic lesion in mice treated with these peptides was
associated with an increase in collagen content. Collagen content
in mice immunized with the combined Cpn peptide is significantly
greater than that in mice immunized with either the MOMP- or
the Omp5-peptide alone. These data suggest that the Cpn-derived
combined peptide may have an additive effect.
Immunization Keyhole limpet hemocyanin (KLH) with the
combined Cpn peptide was associated with intracellular responses
that influence cellular infiltration into atherosclerotic lesions, as the
levels of macrophages, activated CD4+ T cells and dendritic cells
(markers of early lesion formation) were decreased compared with
those in controls [28]. In addition, CD4 T-cells from the mice
immunized with the combined Cpn peptide harbor 2-fold more
Foxp3+ Treg cells compared with either the MOMP peptide or the
Omp5 peptide and approximately 20-fold more compared with
controls. As Th2-type IgG1, and not Th1-type IgG2a, anti-Cpn
peptide antibody titers were observed, indicating an association of
Cpn peptide treatment with Th2 response which was enhanced by
Treg [29,30].
It appears that there is a shift toward decreased pro-
inflammatory cytokine secretion and increased anti-inflammatory
cytokine production in antigen-immunized mice, as the main
biological function of IL-10 and TGF-b is to limit and terminate
the inflammatory responses [31]. IL-10 has been reported to be a
global suppressor of immune responses as well as an immuno-
regulator of the Th-2 cell response [31] while IL-17A (previously
called IL-17) is a unique T helper lineage that regulates tissue
inflammation [32]. Evidence was obtained from CD4+ expressing
pro-atherogenic cytokine IL-17A [33,34], which was shown
decreased IL-17A population in peptide antigen-immunized mice
in this study.
The suppressive function of CD4+CD25+Foxp3 + natural Tregs
appears to require only cell–cell contact or proximity in vitro,
whereas the in vivo function of these cells is associated with
secretion of IL-10 and TGF-b [11,35]. We demonstrated in vitro
that the atheroprotective effect paralleled an induction of Treg
suppression of antigen-specific effector T-cells, thus suggesting
Tregs have an active role in the control of the atherosclerotic
process. Treg cells are characterized by the expression of Foxp3,
which has a crucial role in their suppression function [36].
Figure 7. (A–D) Plasma concentrations of cytokines in Apobtm2SgyLdlrtm1Her/J mice versus controls after immunization with peptide antigens. (E–H)
Concentrations of cytokines in the supernatant of splenocytes stimulated with Apobtm2SgyLdlrtm1Her/J Mice fed with a high-fat diet after
immunization with peptide antigens versus infected controls (N= 6 mice). *P,0.05; **P,0.01; ***P,0.001.
doi:10.1371/journal.pone.0081056.g007
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Collectively, our study has provided evidence that the mech-
anism of lesion reduction by subcutaneous immunization with
Cpn-derived hepta- or nona-peptide is duo to antigen-induced
specific Treg expansion, which suppresses T effector cell
proliferation along with increased atheroprotective cytokines and
decreased proinflammatory cytokines. Notably, IL-17A that was
thought to play a pro-atherogenic role in atherosclerosis [37,38]
was down-regulated, however, the relevance of IL-17A to human
atherosclerosis remains poorly defined.
In conclusion, we have provided proof of principle evidence
that the combined Cpn peptide antigen has an additive effect as
this peptide in most of experiments, if not all, showed
statistically significant difference when compared to either the
MOMP- or the Omp5- peptide antigen used singly (Table S3).
It appears that modulation of atherosclerosis-related autoim-
munity by antigen-specific activation of Tregs represents a novel
approach for the development of bivalent vaccines against
atherosclerosis.
Supporting Information
Figure S1 Detection and quantitation of lesion areas in the aorta
of Ldlrtm1HerApobtm2SgyJ mice infected with Cpn bacteria and fed a
high-fat diet after immunization with Cpn peptides vs controls
infected with Cpn bacteria and fed a high-fat diet after
immunization with KLH only. A. Representative photomicro-
graphs of Oil Red O staining for lipids in cryosections of aortic
root from immunized mice. Lipids are identified by red color. B.
Quantification of ORO staining in the aortic root of Apobtm2Sgy
Ldlrtm1Her/J mice. ORO stained area versus total area (%) at aortic
roots (N= 18 sections, 3 sections per mouse).
(TIF)
Figure S2 Detection and quantitation of collagen contents at
lesion areas in the aorta of Ldlrtm1HerApobtm2SgyJ mice infected with
Cpn bacteria and fed a high-fat diet after immunization with Cpn
peptides vs controls infected with Cpn bacteria and fed a high-fat
diet after immunization with KLH only. A, Representative
photomicrographs and quantitative analysis of collagen (Sirius
Red coloration under polarized light) in atherosclerotic aortas in
individual mice B. Quantitation of collagen content at lesion area
in the aorta of Apobtm2SgyLdlrtm1Her/J mice (N= 18 sections, 3
sections per mouse).
(TIF)
Figure S3 Assessment of IL-17A expression level in splenocytes
from Ldlrtm1HerApobtm2SgyJ mice infected with Cpn bacteria and fed a
high-fat diet after immunization with Cpn peptides vs controls
infected with Cpn bacteria and fed a high-fat diet after immunization
with KLH only. A. Representative flow cytometry plots for IL-17A
expressing CD4+ population in spleen cells. Spleen cells from mice
infected with Cpn bacteria and fed a high-fat diet after immunization
with Cpn peptides and control mice infected with Cpn bacteria and
fed a high-fat diet after immunization with KLH only were purified
using a CD4+ purification kit (Miltenyi Biotec, Surrey, UK)
according to manufacturer’s protocols. B. Bar chart presentation
of flow cytometry analysis. Data represent mean 6 SEM from 3
independent samples.
(TIF)
Figure 8. Assessment of antigen-specific regulatory function in antigen-immunized mice. Inhibition of CD4+CD252 effector T-cell
proliferation by CD4+CD25+ regulatory T–cells isolated from control (KLH–immunized) mice (A,B,F) and peptide-immunized mice when the MOMP-
peptide (A,C,F), the Omp5-pepide (A,D,F), and the combined peptide (A,E,F) were used as antigens. Proliferation of effector cells isolated from
immunized mice alone is indicated in the leftmost bar of each group. Addition of Treg cells to T-effector cells at different ratios was also shown. Data
are expressed as mean of 6 analyses 6 SEM.
doi:10.1371/journal.pone.0081056.g008
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Table S1 Survival and symptoms observed in mice after
infection with different Cpn doses.
(DOCX)
Table S2 Sequence and positivity of the primers on the OmpA
gene encoding Cpn MOMP.
(DOCX)
Table S3 Statistical analysis of the effect of immunization with
the peptides.
(DOCX)
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